Orphan Drugs and Rare Diseases

James E. Valentine () and Frank J. Sasinowski ()
Additional contact information
James E. Valentine: University of Maryland Carey School of Law
Frank J. Sasinowski: University of Rochester School of Medicine, Department of Neurology

Chapter 116 in Principles and Practice of Clinical Trials, 2022, pp 2289-2306 from Springer

Abstract: Abstract There are approximately 8,000 recognized rare diseases affecting close to 30 million people in the United States. Sponsors choosing to engage in research and development of drugs for rare diseases, known as orphan drugs, face challenges and opportunities that are unique to orphan drug development. Small population size, disease heterogeneity, and unknown natural histories, among other factors, must be considered when designing clinical trials for orphan drugs. Additionally, sponsors need to consider the quality and quantity of clinical trial information needed to support the approval of an orphan drug. To further understand these unique challenges, sponsors should partner with patient groups who can provide disease-specific perspectives and experiences, as well as conduct natural history studies, to better inform the design and evaluation of results from clinical trials. Novel technologies are changing the clinical trial landscape which provide sponsors a unique opportunity to employ novel, lifesaving technologies that can truly “cure” rare diseases. Incentives provided by the Orphan Drug Act and other FDA policies, such as market exclusivity, priority review vouchers, and tax credits, recognize the unique status of orphan drugs and serve to stimulate the development of these products.

Keywords: Food and Drug Administration; Rare disease; Orphan drugs; Orphan Drug Act; Incentives; Challenges; Flexibility; Patient-focused drug development; Natural history studies; Targeted therapies (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_253

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_253

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().